HER2 is unlikely to be involved in directly regulating angiogenesis in human breast cancer

Applied Immunohistochemistry and Molecular Morphology

Volumn 14, Issue 2, 2006, Pages 138-145

  Vogl, Georgia ^a,c   Bartel, Heidi ^a,b   Dietze, Otto ^a   Hauser Kronberger, Cornelia ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^b UNIVERSITY OF SALZBURG   (Austria)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Angiogenesis; Human epidermal growth factor receptors 1 and 2; Invasive breast carcinoma; Microvessel density; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; THYMIDINE PHOSPHORYLASE; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST CANCER; COMPUTER ANALYSIS; CORRELATION ANALYSIS; EVALUATION RESEARCH; GENE AMPLIFICATION; GENE EXPRESSION REGULATION; GROWTH REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TUMOR GROWTH;

ANGIOGENESIS INDUCING AGENTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, GROWTH FACTOR; UP-REGULATION;

EID: 33745375000     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000168591.58721.a6     Document Type: Article

References (34)

1. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia. 2001;6:393-406.
2. Yang W, Klos K, Yang Y, et al. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer (Phila). 2002;94:2855-2861.
3. Yen L, You XL, Al Moustafa AE, et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene. 2000;19:3460-3469.
4. Boudreau N, Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res. 2003;5:140-146.
5. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncoaene in human breast and ovarian cancer. Science. 1989;244:707-712.
6. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000;5(Suppl. 1):37-44.
7. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
8. Remmele W, Stegner HE. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987;8:138-140.
9. Fox SB, Westwood M, Moghaddam A, et al. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br J Cancer. 1996;73:275-280.
10. Lee AHS, Dublin EA, Bobrow LG. Angiogenesis and expression of thymidine phosphorylase by inflammatory and carcinoma cells in ductal carcinoma in situ of the breast. J Pathol. 1999;187:285-290.
11. Lee JS, Kim HS, Jung JJ, et al. Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and Her-2/neu protein expression. Appl Immunol Mol Morphol. 2002;10:289-295.
12. Adams J, Carder PJ, Downey S, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000;60:2898-2905.
13. Granato AM, Nanni O, Falcini F, et al. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools? Breast Cancer Res. 2004;6:R38-R45.
14. Konecny GE, Meng YG, Untch M, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004;10:1706-1716.
15. Blackwell KL, Dewhirst MW, Liotcheva V, et al. HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res. 2004;10:4083-4088.
16. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992;24:85-95.
17. Witton CJ, Reeves JR, Going JJ, et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290-297.
18. Worthylake R, Opresko LK, Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem. 1999;274:8865-8874.
19. Toi M, Inada K, Hoshina S, et al. Vascular endothelial growth factor and platelet derived-endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res. 1995;1:961.
20. Toi M, Yamamoto Y, Taniguchi T, et al. Regulation of endothelial growth factor expressions in breast cancer. Gan To Kagaku Ryoho. 1996;23(Suppl. 1):75-79.
21. Axelsson K, Ljung BME, Moore DH II, et al. Tumour angiogenesis as a prognostic assay for invasive ductal breast carcinoma. J Natl Cancer Inst. 1995;87:997-1008.
22. Guidi AJ, Berry DA, Broadwater G, et al. Association of angiogenesis and disease outcome in node-positive breast cancer patients treated with adjuvant cyclophosphamide, doxorubicin, and fluorouracil: a Cancer and Leukaemia Group B correlative science study from protocols 8541/8869. J Clin Oncol. 2002;20:732-742.
23. Ludovini V, Sidoni A, Pistola L, et al. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat. 2003;81:159-168.
24. Weidner N, Folkman J, Pozza F, et al. Tumour angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84:1875-1887.
25. De Jong JS, Diest PJ, Baak JPA. Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology. 2000;36:306-312.
26. Weidner N, Semple JP, Welch WR, et al. Tumour angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
27. Koukourakis MI, Manolas C, Minopoulos G, et al. Angiogenesis relates to estrogen receptor negativity, c-erbB-2 overexpression and early relapse in node-negative ductal carcinoma of the breast. Int J Surg Pathol. 2003;11:29-34.
28. La Rosa S, Uccella S, Finzi G, et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumours: correlation with microvessel density and clinicopathological features. Hum Pathol. 2003;34:18-27.
29. Boudreau N, Myers C. Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res. 2003;5:140-146.
30. Yoshiji H, Hartris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast cancer carcinoma cells. Cancer Res. 1997;57:3924-3928.
31. Czerwenka K, Lu Y, Heuss F. Amplification and expression of the c-erbB-2 oncogene in normal, hyperplastic, and malignant endometria. Int J Gynecol Pathol. 1995;14:98-106.
32. Yonenaga F, Takasaki T, Ohi Y, et al. The expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor is correlated to angiogenesis in breast cancer. Pathol Int. 1998;48:850-856.
33. Bevilacqua P, Barbareschi M, Verderio P, et al. Prognostic value of intratumoural microvessel density, a measure of tumour angiogenesis, in node-negative breast carcinoma: result of a multiparametric study. Breast Cancer Res Treat. 1995;36:205-217.
34. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion antibodies, as indicator of node metastases and survival in breast cancer. Lancet. 1992;340:1120-1124.